Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures

J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1307-e1309. doi: 10.1111/jdv.19302. Epub 2023 Jul 14.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Janus Kinase Inhibitors* / adverse effects
  • Pharmacovigilance
  • Risk Assessment
  • Treatment Outcome

Substances

  • Janus Kinase Inhibitors

Grants and funding